Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

Stopped Low likelihood to usedrug in clinic practice based on emergining AE profile and data from front line clinical trials

Conditions

• Chronic Lymphocytic Leukemia

Interventions

• OTHER: Biospecimen Collection

Sponsor

Abramson Cancer Center at Penn Medicine